Role of rosuvastatin in lipid-lowering therapy today;A rosuvastatin klinikai jelentosége napjaink lipidológiai gyógyszerelésében

Orvosi Hetilap

Volumn 151, Issue 35, 2010, Pages 1424-1428

  Ábel, Tatjána ^a   Fehér, János ^b  

^a Allami Egeszsegugyi Kozpont State Health Center   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

atherosclerosis; cholesterol; therapy

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; CHOLESTEROL; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; DRUG TOLERABILITY; HUMAN; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; REMISSION; REVIEW; SECONDARY PREVENTION; ACUTE CORONARY SYNDROME; BLOOD; COMPLICATION; DRUG EFFECTS; HYPERCHOLESTEROLEMIA; META ANALYSIS (TOPIC); METABOLISM;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHOLESTEROL; DISEASE PROGRESSION; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; META-ANALYSIS AS TOPIC; PYRIMIDINES; SULFONAMIDES;

EID: 77956312518     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28937     Document Type: Review

References (32)

1. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-1389.
2. Lipid Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long Trem Intervention with Pravastatin in Ischemic Disease (LIPID) study group. N. Engl. J. Med., 1998, 339, 1349-1357.
3. Downs, J. R., Clearfield, M., Weis, S. és mtsai: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279, 1615-1622.
4. Baigent, C., Keech, A., Kearney, P. M. és mtsai: Cholesterol Treatment Trialist' (CTT) Collaborators. Efficacy and safety of cholesterol- lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet, 2005, 366, 1267-1278.
5. Farmer, J. A.: A statinok pleiotrop hatásai. Current Atherosclerosis Report (magyar kiadás), 2002, 2, 208-217.
6. Liao, J. K.: Beyond lipid lowering: the role of statins in vascular protection. Int. J. Cardiol., 2002, 86, 5-18.
7. Bellosta, S., Ferri, N., Bernini, F. és mtsai: Non-lipid-related effects of statins. Ann. Med., 2000, 32, 164-176.
8. Narla, V., Blaha, M. J., Blumenthal, R. S. és mtsai: The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences. Vasc. Health Risk Manag., 2009, 5, 1033-1042.
9. Szollá L., Pados Gy.: Összefoglalás-A IV. Magyar Kardiovaszkuláris Konszenzus Konferencia ajánlásairó l. Metabolizmus, 2010, 8, 9-12.
10. Kapur, N. K.: Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert. Rev. Cardiovasc. Ther., 2007, 5, 161-175.
11. Jones, P. H., Davidson, M. H., Stein, E. A. és mtsai: STELLAR Study Goup. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses. Am. J. Cardiol., 2003, 92, 152-160.
12. Schuster, H., Barter, P. J., Stender, S. és mtsai: Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am. Heart. J., 2004, 147, 705-712.
13. Rubba, P., Marotta, G., Gentile, M.: Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vasc. Health Risk Manag., 2009, 5, 343-352.
14. Nicholls, S. J., Tuzcu, E. M., Sipahi, I. és mtsai: Statins, high-density lipoprotein cholesterol and regression of coronary atherosclerosis. JAMA, 2007, 297, 499-508.
15. Nissen, S. E., Tuzcu, E. M., Schoenhagen, P. és mtsai: REVERSAL Investigators. Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA, 2004, 291, 1071-1080.
16. Nissen, S. E., Nicholls, S. J., Sipahi, I. és mtsai: ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA, 2006, 295, 1556-1565.
17. Course, J. R., Raichlen, J. S., Riley, W. A. és mtsai: METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low risk individuals with subclinical atherosclerosis. JAMA, 2007, 297, 1344-1353.
18. Hulten, E., Jackson, J. L., Douglas, K. és mtsai: The effect of early, intensive statin therapy on acute coronary syndrome: a metaanalysis of randomized controlled trials. Arch. Intern. Med., 2006, 166, 1814-1821.
19. Josan, K., Majumdar, S. R., McAlister, F. A.: The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ, 2008, 178, 576-584.
20. Pitt, B., Loscalzo, J., Ycas, J. és mtsai: Lipid levels after acute coronary syndromes. J. Am. Coll. Cardiol., 2008, 51, 1440-1445.
21. Walldius, G., Jungner I.: The apoB/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and target for lipid-lowering therapy - a review of the evidence. J. Intern. Med., 2006, 259, 493-519.
22. Yusuf, S., Hawken, S., Ounpuu, S. és mtsai: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004, 364, 937-952.
23. Walldius, G., Jungner, I.: Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipidmodifying therapy. J. Intern. Med., 2004, 255, 188-205.
24. Sniderman, A. D., Furberg, C. D., Keech, A. és mtsai: Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet, 2003, 361, 777-780.
25. Lablanche, J. M., Leone, A., Merkely, B. és mtsai: Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ration in patients with acute coronary syndrome: Results of the CENTAURUS study. Archives Cardiovascular Diseases, 2010, 103, 160-169.
26. Pai, P. K., Pischon, T., Ma, J. és mtsai: Infl ammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med., 2004, 351, 2599-2610.
27. Emerging Risk Factors Collaboration: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, 2010, 375, 132-140.
28. Ridker, P. M., Rifai, N., Pfeiffer, M. A. és mtsai: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigator. Circulation, 1999, 100, 230-235.
29. Jialal, I., Stein, D., Balis, D. és mtsai: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 2001, 103, 1933-1935.
30. Ridker, P. M., Danielson, E., Fonseca, F. A. H. és mtsai: JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 2008, 359, 2195-2207.
31. Ridker, P. M., Danielson, E., Fonseca, F. A. H. és mtsai: Reduction in C-reactive protein and LDL-cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, 2009, 373, 1175-1182.
32. MÁk L., Katona A.: A lipidcélértekektöl a JUPITER vizsgálatig. Az Iráyelvekben elöírt lipidszintek elérésenk jelentösége és a gyakorlat hiáyosságai. Orv. Hetil., 2009, 150, 2012-2018.